[Non-lipid effects of statins: myth or fact?]

Wien Med Wochenschr. 2003;153(11-12):244-9. doi: 10.1046/j.1563-258x.2003.03028.x.
[Article in German]

Abstract

Hydroxy-methylglutaryl coenzyme A reductase-inhibitors (HMG-CoA [statins]) are currently the most effective method to pharmacologically decrease total plasma cholesterol levels. A number of multicenter studies have demonstrated, that statins administered for several years lead to a significant reduction of cardiovascular events and mortality compared with placebo. Apart from the well known LDL- and cholesterol lowering effect, statins have been postulated to exert beneficial effects on mortality due to so called 'non-lipid effects'. There is circumstantial evidence from a number of experimental studies that statins can improve endothelial function, exert anti-inflammatory and anti-oxidative effects, stabilize arteriosclerotic plaque and inhibit proliferation and activation of smooth muscle cells. However, the clinical implications of these beneficial 'non-lipid effects' are unclear, but appear to exert only a minor role in comparison to the lowering effect of statins on total plasma cholesterol levels.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antioxidants / adverse effects
  • Antioxidants / therapeutic use*
  • Arteriosclerosis / drug therapy*
  • Arteriosclerosis / mortality
  • Arteriosclerosis / physiopathology
  • Cell Division / drug effects
  • Cell Division / physiology
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiopathology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypercholesterolemia / drug therapy*
  • Hypercholesterolemia / mortality
  • Hypercholesterolemia / physiopathology
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / therapeutic use*
  • Multicenter Studies as Topic
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / physiopathology
  • Randomized Controlled Trials as Topic
  • Survival Rate

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antioxidants
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents